Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Acumen Pharmaceuticals, Inc. (ABOS : NSDQ)
 
 • Company Description   
Acumen Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It involved in developing a novel disease for Alzheimer. The company's product pipeline consist ACU193. Acumen Pharmaceuticals Inc. is based in CHARLOTTESVILLE, Va.

Number of Employees: 17

 
 • Price / Volume Information   
Yesterday's Closing Price: $3.47 Daily Weekly Monthly
20 Day Moving Average: 192,578 shares
Shares Outstanding: 40.50 (millions)
Market Capitalization: $140.54 (millions)
Beta:
52 Week High: $26.98
52 Week Low: $3.02
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -14.32% -3.50%
12 Week -35.50% -29.09%
Year To Date -48.67% -37.28%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
427 PARK ST.
-
CHARLOTTESVILLE,VA 22902
USA
ph: 434-297-1000
fax: -
investors@acumenpharm.com http://www.acumenpharm.com
 
 • General Corporate Information   
Officers
Daniel O'Connell - Chief Executive Officer
William Matthew Zuga - Chief Financial Officer and ChiefBusiness Officer
Nathan B. Fountain - Director
Jeffrey L. Ives - Director
Sean Stalfort - Director

Peer Information
Acumen Pharmaceuticals, Inc. (CORR.)
Acumen Pharmaceuticals, Inc. (RSPI)
Acumen Pharmaceuticals, Inc. (CGXP)
Acumen Pharmaceuticals, Inc. (BGEN)
Acumen Pharmaceuticals, Inc. (GTBP)
Acumen Pharmaceuticals, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 00509G209
SIC: 2836
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/15/22
Share - Related Items
Shares Outstanding: 40.50
Most Recent Split Date: (:1)
Beta:
Market Capitalization: $140.54 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.95 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: 11.99% Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/15/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 0.65
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/22 - -17.45
12/31/21 - -55.59
09/30/21 - -221.88
ROA
03/31/22 - -13.08
12/31/21 - -29.40
09/30/21 - -35.55
Current Ratio
03/31/22 - 48.81
12/31/21 - 38.60
09/30/21 - 137.62
Quick Ratio
03/31/22 - -
12/31/21 - 38.60
09/30/21 - 137.62
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -28,271.13
Book Value
03/31/22 - 5.34
12/31/21 - 5.56
09/30/21 - 5.77
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©